Market Overview:
The global Dostinex market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of Parkinson's disease (PD) and hyperprolactinemia, and increasing demand for cabergoline in emerging markets. The global Dostinex market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into 0.5mg/Pcs, 1mg/Pcs, 2mg/Pcs segments. On the basis of application, the market is segmented into Parkinson's disease (PD), hyperprolactinemia segments. Geographically,the global Dostinexmarketis dividedinto North America,, Europe,, Asia Pacificand Middle East & Africa regions.
Product Definition:
It is a medication used to treat Parkinson's disease, hyperprolactinemia, and hormone disorders.
0.5mg/Pcs:
The 0.5mg/Pcs, also known as dihydroergotamine or Dostinex, is a drug that's used to treat migraine and is also used in the treatment of cluster headache. It’s an ergot alkaloid derived from ergoline which is extracted from certain fungi including Coniothyrium minitans and C. glutamicum among others through chemical synthesis or fermentation.
1mg/Pcs:
1mg/Pcs is used for the treatment of angina pectoris, hypertension, and cardiac failure. It is also used as an anti-hypertensive medication. The medicine works by relaxing the muscles of the heart and reducing blood pressure.
The medicine was approved by FDA in 1960s for use as an anti-hypertensive drug; however, it has gained popularity as a generic name for treatment of angina pectoris since 1980s.
Application Insights:
The Parkinson¢â‚¬â„¢s disease segment accounted for the largest revenue share in 2017 and is projected to continue its dominance over the forecast period. The increasing prevalence of PD, coupled with rising awareness about available treatment options, is expected to drive demand for dostinex in PD treatment.
Parkinson¢â‚¬â„¢s disease (PD) is a chronic disorder characterized by bradykinesia (slowness), rigidity and tremor. It affects around 1 million individuals in North America and Europe as per estimates from Parkinson¢â‚¬â„¢s U.K., while it affects nearly 60 million people across the globe according to statistics from WHO.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to increasing R&D activities, rising healthcare expenditure, and high adoption of innovative drugs in this region. Moreover, presence of key companies such as Pfizer Inc., Elan Corporation and Parkinson’s Foundation International (USA) that are engaged in extensive research & development activities will boost the growth further.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rise in disposable income coupled with growing awareness about available treatment options for various neurodegenerative diseases including Parkinson’s disease (PD). In addition, increase government initiatives aimed at improving healthcare infrastructure are likely to contribute towards regional market growth over next eight years.
Growth Factors:
- Increasing prevalence of infertility and rising demand for fertility treatments
- Growing awareness about the benefits of Dostinex among women
- Rising number of pregnancies in older women
- Increasing use of Dostinex in combination with other fertility drugs
- Launch of new products by key players
Scope Of The Report
Report Attributes
Report Details
Report Title
Dostinex Market Research Report
By Type
0.5mg/Pcs, 1mg/Pcs, 2mg/Pcs
By Application
Parkinson's Disease (PD), Hyperprolactinemia, Other
By Companies
Pfizer, Teva, Sun Pharmaceutical, Mylan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
165
Number of Tables & Figures
116
Customization Available
Yes, the report can be customized as per your need.
Global Dostinex Market Report Segments:
The global Dostinex market is segmented on the basis of:
Types
0.5mg/Pcs, 1mg/Pcs, 2mg/Pcs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Parkinson's Disease (PD), Hyperprolactinemia, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Teva
- Sun Pharmaceutical
- Mylan
Highlights of The Dostinex Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 0.5mg/Pcs
- 1mg/Pcs
- 2mg/Pcs
- By Application:
- Parkinson's Disease (PD)
- Hyperprolactinemia
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dostinex Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dostinex is a medication used to treat Alzheimer's disease. It works by slowing the progression of the disease.
Some of the major players in the dostinex market are Pfizer, Teva, Sun Pharmaceutical, Mylan.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dostinex Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dostinex Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dostinex Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dostinex Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dostinex Market Size & Forecast, 2018-2028
4.5.1 Dostinex Market Size and Y-o-Y Growth
4.5.2 Dostinex Market Absolute $ Opportunity
Chapter 5 Global Dostinex Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Dostinex Market Size Forecast by Type
5.2.1 0.5mg/Pcs
5.2.2 1mg/Pcs
5.2.3 2mg/Pcs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Dostinex Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Dostinex Market Size Forecast by Applications
6.2.1 Parkinson's Disease (PD)
6.2.2 Hyperprolactinemia
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dostinex Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dostinex Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Dostinex Analysis and Forecast
9.1 Introduction
9.2 North America Dostinex Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Dostinex Market Size Forecast by Type
9.6.1 0.5mg/Pcs
9.6.2 1mg/Pcs
9.6.3 2mg/Pcs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Dostinex Market Size Forecast by Applications
9.10.1 Parkinson's Disease (PD)
9.10.2 Hyperprolactinemia
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Dostinex Analysis and Forecast
10.1 Introduction
10.2 Europe Dostinex Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Dostinex Market Size Forecast by Type
10.6.1 0.5mg/Pcs
10.6.2 1mg/Pcs
10.6.3 2mg/Pcs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Dostinex Market Size Forecast by Applications
10.10.1 Parkinson's Disease (PD)
10.10.2 Hyperprolactinemia
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Dostinex Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Dostinex Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Dostinex Market Size Forecast by Type
11.6.1 0.5mg/Pcs
11.6.2 1mg/Pcs
11.6.3 2mg/Pcs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Dostinex Market Size Forecast by Applications
11.10.1 Parkinson's Disease (PD)
11.10.2 Hyperprolactinemia
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Dostinex Analysis and Forecast
12.1 Introduction
12.2 Latin America Dostinex Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Dostinex Market Size Forecast by Type
12.6.1 0.5mg/Pcs
12.6.2 1mg/Pcs
12.6.3 2mg/Pcs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Dostinex Market Size Forecast by Applications
12.10.1 Parkinson's Disease (PD)
12.10.2 Hyperprolactinemia
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Dostinex Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Dostinex Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Dostinex Market Size Forecast by Type
13.6.1 0.5mg/Pcs
13.6.2 1mg/Pcs
13.6.3 2mg/Pcs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Dostinex Market Size Forecast by Applications
13.10.1 Parkinson's Disease (PD)
13.10.2 Hyperprolactinemia
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dostinex Market: Competitive Dashboard
14.2 Global Dostinex Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Teva
14.3.3 Sun Pharmaceutical
14.3.4 Mylan
